Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
TOKYO, Nov. 19, 2018 /CNW/ -- Daiichi Sankyo (JP: 4568.T, OTC Pink: DSNKY), based in Tokyo, Japan, focused on the pharmaceutical business, today announced that the November 15 presentation from Daiichi Sankyo, Senior Director, IR group Mr. Junichi Onuma, is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.
Daiichi Sankyo presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- 2018.11.06 EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
- 2018.10.26 Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate [Fam-] Trastuzumab Deruxtecan (DS-8201) with Avelumab and a DNA Damage Response Inhibitor in Patients with HER2 Expressing and Mutated Solid Tumors
- 2018.10.22 Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
Learn more about the event at www.VirtualInvestorConferences.com.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Daiichi Sankyo
For further information: Daiichi Sankyo Co., Ltd., Shinichi Kuga, Associate Director, IR Group, [email protected], +81-3-6225-1156; VirtualInvestorConferences.com, John M. Viglotti, 212-729-8350, [email protected], http://www.daiichisankyo.com